Industries - Drug Device Combination Market Analysis by Product (Infusion Pumps, Orthopaedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters, Photodynamic Therapy Devices, Wound Care Products, Transdermal Patches), and by Region – Forecast to 2026

Ablation Technology Market Analysis

Drug Device Combination Market Analysis by Product (Infusion Pumps, Orthopaedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters, Photodynamic Therapy Devices, Wound Care Products, Transdermal Patches), and by Region – Forecast to 2026
July 2021

SKU: N/A Category:
Clear
  • Description
  • Additional information
  • Enquire about

Description

Drug Device Combination Market Analysis by Product (Infusion Pumps, Orthopaedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters, Photodynamic Therapy Devices, Wound Care Products, Transdermal Patches), and by Region - Forecast to 2026

Published: July-21 | Historical Data: 2018-2020 | Base Year: 2020
SKU: ICI-HC-1131 | Number of Pages: 145 | Category: Medical Devices

The global drug device combination market size is projected to reach USD 193.8 billion by 2026, exhibiting a compounded annual growth rate (CAGR) of 7.4% during the forecast period 2020-2026.

The drug device combination products are basically medical devices which contains active pharmaceutical ingredients making it useful for therapeutic purposes. These combination products help for the effective and safe drug delivery process leading to the treatment of various diseases and disorders such as diabetes, cancer, respiratory complications, cardiovascular diseases and wound healing. These combination products include inhalers, infusion pumps, antimicrobial catheters, drug eluting stents, orthopaedic combination products, photodynamic therapy devices, wound care products, transdermal patches.

Rising preference of patient & medical practitioners for less invasive surgeries coupled with dependable alternative treatment for dosing are key drivers for the growth of the global drug device combination market. Additionally, technological advancements, novel product development, cross-infection cases during the COVID-19 pandemic, and growing demand for biologics in the treatment of chronic diseases are some of the other drivers propelling the market growth. For instance, according to the World Health Organisation (WHO), most deaths annually are due to chronic diseases such as cardiovascular diseases (17.9 million), cancer (9.3 million), respiratory complications (4.1 million), and diabetes (1.5 million). However, lack of technical knowledge for medical devices such as reliability and robustness of the medical devices are expected to restrain the global market growth.

Drug Device Combination Market

Read more about the market dynamics, Request a Sample Copy

Market Driver Analysis

Increasing prevalence of chronic diseases leading to the growth of drug device combination market

The prevalence of chronic diseases like cardiovascular, respiratory, cancer, diabetes is increasing across the globe. The factors influencing these chronic diseases include globalization of unhealthy lifestyles, ageing population, and adoption of sedentary lifestyle by people. These factors lead to high blood pressure, obesity and cardiovascular diseases which is the leading cause of premature deaths. These chronic diseases kill approximately 4.1 million people which is 71% of all the deaths globally. The vulnerable population for these chronic diseases is the older age groups. This increase in chronic diseases dominate the global healthcare market leading to innovations and advancements in drug delivery systems and growth in new formulations.

Key Market Restraint

Concerns related to device reliability hinders the growth of the market

A drug device combination product is used as a therapy to treat various chronic diseases. Challenges such as inaccurate administration of drug can be caused if the device for drug delivery is not reliable and robust. Also, various factors such as the handling of the device by the patients is also important for reliability of the device. Due to such challenges the U.S. Food and Drug Administration (FDA) has put stringent regulations which focusses on three aspects such as the user interface, intended users (patients) and the environment where the device is going to be operated leading to delayed product approval procedures.

Market Segmentation and Share Analysis

By Product

Based on product, the market is segmented into infusion pumps, orthopaedic combination products, drug eluting stents, inhalers, antimicrobial catheters, photodynamic therapy devices, wound care products, transdermal patches, and others. In 2020, the transdermal patches segment accounted for the maximum revenue share. This is attributed to the growing need for administration of drugs by self in incidences of long-term treatment of diseases. Inhalers segment is projected to grow at a significant CAGR during the forecast period. This is attributed to rising cases of respiratory illness and increasing number of asthma patients globally.

Regional Insights

In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the technological advancements, modern medical services & treatment, novel product launches, and high investments in R&D in this region. For instance, in February 2020, Flowonix Medical received approval for its Prometra delivery System from the U.S. Food and Drug Administration (FDA). This drug delivery system contains a specialized pain medication which is implanted under the skin of the abdomen that connects to a narrow catheter leading to a targeted area within the spinal cord.

North America Drug Device Combination Market Size (2018-2026), USD Billion

North America Drug Device Combination Market Size (2018-2026), USD Billion

Read more about the market dynamics, Request a Sample Copy

Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the rising incidences of chronic diseases, growing demand for advanced medication and treatment, strengthening medical infrastructure, and growing focus of biopharmaceutical companies in this region.

 

Competitor Insights

Some of the key players in the drug device combination market are W. L. Gore & Associates, Inc. (U.S.); Becton, Dickinson and Company (U.S.); Teleflex Incorporated (U.S.); Novartis International AG (Switzerland); Boston Scientific Corporation (U.S.); AbbVie Inc. (U.S.); Abbott Laboratories (U.S.); Medtronic plc (Ireland); Stryker Corporation (U.S.) and Terumo Corporation (Japan). The leading players operating in the drug device combination industry are adopting various strategies including R&D investments, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

Industry Developments

  • In June 2021, Abbott launched a Amplatzer Steerable Delivery Sheath which is used with Amplatzer Amulet Left Atrial Appendage (LAA) Occluder for atrial fibrillation.
  • In June 2020, Sun Pharmaceutical Industries Ltd. launched LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U (Light Photodynamic Therapy Illuminator) for treating patients suffering from different types of skin cancer.

Research Scope and Segments

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2018 to 2026. The drug device combination market report is categorized into the following segments and subsegments:

Drug Device Combination Market, By Product (Revenue, USD Billion, 2018 – 2026)

  • Infusion Pumps
    • Insulin
    • Disposables
    • Volumetric
    • Syringes
    • Implantables
    • Ambulatory
  • Orthopedic Combination Products
    • Antibiotic Bone Cement
    • Bone Graft Implants
  • Drug Eluting Stents
    • Peripheral Vascular Stents
    • Coronary Stents
  • Inhalers
    • Nebulizers
    • Dry Powder
    • Metered Dose
  • Antimicrobial Catheters
    • Cardiovascular
    • Urological
    • Others
  • Photodynamic Therapy Devices
  • Wound Care Products
  • Transdermal Patches
  • Others

Drug Device Combination Market, By Region (Revenue, USD Billion, 2018 – 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Drug Device Combination Market Report:

Key Parameters Details
Data Availability 2018-2026
Historical Years 2018-2020
Base Year Considered 2020
Forecast Data 2021-2026
Company Profiles 10
Companies Considered >40
Value Units Value in USD and CAGR in %
Market Segments Product
Regional Coverage
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA)
Key Market Players
  • W. L. Gore & Associates, Inc.
  • Becton, Dickinson and Company
  • Teleflex Incorporated
  • Novartis International AG
  • Boston Scientific Corporation
  • AbbVie Inc.
  • Abbott Laboratories
  • Medtronic plc
  • Stryker Corporation
  • Terumo Corporation
Custom Analysis Customization up to 60 analyst hours (15%)

Drug Device Combination Market, By Product (Revenue, USD Billion, 2018 – 2026)

  • Infusion Pumps
    • Insulin
    • Disposables
    • Volumetric
    • Syringes
    • Implantables
    • Ambulatory
  • Orthopedic Combination Products
    • Antibiotic Bone Cement
    • Bone Graft Implants
  • Drug Eluting Stents
    • Peripheral Vascular Stents
    • Coronary Stents
  • Inhalers
    • Nebulizers
    • Dry Powder
    • Metered Dose
  • Antimicrobial Catheters
    • Cardiovascular
    • Urological
    • Others
  • Photodynamic Therapy Devices
  • Wound Care Products
  • Transdermal Patches
  • Others

Drug Device Combination Market, By Region (Revenue, USD Billion, 2018 – 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA
1. Research Methodology
 1.1. Research Objective
 1.2. Study Scope: Market Segments
 1.3. Study Timeframe, Limitations & Currency
 1.4. Domain-Assisted Cognition (DAC) Framework
  1.4.1. Three-stage Research Methodology
   1.4.1.1. Understand Ecosystem
    1.4.1.1.1. Secondary Research
    1.4.1.1.2. Primary Research
    1.4.1.1.3. Internal Repository
   1.4.1.2. Synthesize Information
    1.4.1.2.1. Data Analysis
    1.4.1.2.2. Data Triangulation
   1.4.1.3. Predict/Project Growth
    1.4.1.3.1. Market Size Estimation
     1.4.1.3.1.1. Bottom-up Approach
     1.4.1.3.1.2. Top-down Approach
    1.4.1.3.2. Data Validation
  1.4.2. Two-stage Quality Check Mechanism
   1.4.2.1. Inspection & Reporting
   1.4.2.2. Quality Audit
2. Market Summary
 2.1. Market Definition & Market Landscape
 2.2. Market Segment Snapshot
 2.3. Geographic Market Snapshot
3. Market Dynamics
 3.1. Market Driver Analysis
  3.1.1. Growing need for sophisticated drug delivery devices requiring minimal invasive procedures
  3.1.2. Advancements in technology
  3.1.3. Rising demand for point of care treatment
  3.1.4. Government and private healthcare organizations support
  3.1.5. Growing consumer awareness
  3.1.6. Intensifying medical compensation procedure
 3.2. Market Restraint Analysis
  3.2.1. Expensive technology costs
  3.2.2. Lack of technical know-how for medical devices
 3.3. Market Opportunities
  3.3.1. Mapping untapped application of advanced drug delivery technology in unexplored clinical application
  3.3.2. Strengthening medical infrastructure and growing medical expenditure in emerging economies
4. Industry Outlook
 4.1. Key Market Trends
 4.2. Value Chain Analysis
 4.3. Porter’s 5 Forces Analysis
 4.4. Pricing Analysis (2018-2020)
 4.5. Product Benchmarking
5. Covid-19 Impact and Deviation Analysis
 5.1. Covid-19 Prevalence Analysis
 5.2. Key Market Trends
 5.3. Market Size Deviation Analysis (2020-2026)
6. Drug Device Combination Market Size and Forecast, by Product (2018-2026), USD Million
 6.1. Infusion Pumps
  6.1.1. Insulin
  6.1.2. Disposables
  6.1.3. Volumetric
  6.1.4. Syringes
  6.1.5. Implantables
  6.1.6. Ambulatory
 6.2. Orthopedic Combination Products
  6.2.1. Antibiotic Bone Cement
  6.2.2. Bone Graft Implants
 6.3. Drug Eluting Stents
  6.3.1. Peripheral Vascular Stents
  6.3.2. Coronary Stents
 6.4. Inhalers
  6.4.1. Nebulizers
  6.4.2. Dry Powder
  6.4.3. Metered Dose
 6.5. Antimicrobial Catheters
  6.5.1. Cardiovascular
  6.5.2. Urological
  6.5.3. Others
 6.6. Photodynamic Therapy Devices
 6.7. Wound Care Products
 6.8. Transdermal Patches
 6.9. Others
7. Drug Device Combination Market, Regional Analysis (2018-2026), USD Million
 7.1. North America
  7.1.1. Introduction
   7.1.1.1. Market Size & Forecast, by Product (2018-2026), USD Million
   7.1.1.2. Market Size & Forecast, by Country (2018-2026), USD Million
  7.1.2. U.S.
   7.1.2.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.1.3. Canada
   7.1.3.1. Market Size & Forecast, by Product (2018-2026), USD Million
 7.2. Europe
  7.2.1. Introduction
   7.2.1.1. Market Size & Forecast, by Product (2018-2026), USD Million
   7.2.1.2. Market Size & Forecast, by Country (2018-2026), USD Million
  7.2.2. Germany
   7.2.2.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.3. UK
   7.2.3.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.4. France
   7.2.4.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.5. Spain
   7.2.5.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.6. Italy
   7.2.6.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.7. Russia
   7.2.7.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.2.8. Rest of Europe
   7.2.8.1. Market Size & Forecast, by Product (2018-2026), USD Million
 7.3. Asia Pacific (APAC)
  7.3.1. Introduction
   7.3.1.1. Market Size & Forecast, by Product (2018-2026), USD Million
   7.3.1.2. Market Size & Forecast, by Country (2018-2026), USD Million
  7.3.2. China
   7.3.2.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.3.3. Japan
   7.3.3.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.3.4. India
   7.3.4.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.3.5. Australia
   7.3.5.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.3.6. South Korea
   7.3.6.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.3.7. Rest of Asia Pacific
   7.3.7.1. Market Size & Forecast, by Product (2018-2026), USD Million
 7.4. Latin America (LATAM)
  7.4.1. Introduction
   7.4.1.1. Market Size & Forecast, by Product (2018-2026), USD Million
   7.4.1.2. Market Size & Forecast, by Country (2018-2026), USD Million
  7.4.2. Brazil
   7.4.2.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.4.3. Mexico
   7.4.3.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.4.4. Argentina
   7.4.4.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.4.5. Rest of LATAM
   7.4.5.1. Market Size & Forecast, by Product (2018-2026), USD Million
 7.5. Middle East & Africa (MEA)
  7.5.1. Introduction
   7.5.1.1. Market Size & Forecast, by Product (2018-2026), USD Million
   7.5.1.2. Market Size & Forecast, by Country (2018-2026), USD Million
  7.5.2. South Africa
   7.5.2.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.5.3. Saudi Arabia
   7.5.3.1. Market Size & Forecast, by Product (2018-2026), USD Million
  7.5.4. Rest of MEA
   7.5.4.1. Market Size & Forecast, by Product (2018-2026), USD Million
8. Competitor Analysis
 8.1. Market Player Comparison
 8.2. Product-wise Player Mapping
 8.3. Region-wise Player Mapping
 8.4. Market Share Analysis
 8.5. Market Position Analysis
 8.6. Recent Development Analysis
9. Company Profiles
 9.1. W. L. Gore & Associates, Inc. (U.S.)
  9.1.1. Company Overview
  9.1.2. Company Financials
  9.1.3. Product Portfolio
  9.1.4. Recent Developments
 9.2. Becton, Dickinson and Company (U.S.)
  9.2.1. Company Overview
  9.2.2. Company Financials
  9.2.3. Product Portfolio
  9.2.4. Recent Developments
 9.3. Teleflex Incorporated (U.S.)
  9.3.1. Company Overview
  9.3.2. Company Financials
  9.3.3. Product Portfolio
  9.3.4. Recent Developments
 9.4. Novartis International AG (Switzerland)
  9.4.1. Company Overview
  9.4.2. Company Financials
  9.4.3. Product Portfolio
  9.4.4. Recent Developments
 9.5. Boston Scientific Corporation (U.S.)
  9.5.1. Company Overview
  9.5.2. Company Financials
  9.5.3. Product Portfolio
  9.5.4. Recent Developments
 9.6. AbbVie Inc. (U.S.)
  9.6.1. Company Overview
  9.6.2. Company Financials
  9.6.3. Product Portfolio
  9.6.4. Recent Developments
 9.7. Abbott Laboratories (U.S.)
  9.7.1. Company Overview
  9.7.2. Company Financials
  9.7.3. Product Portfolio
  9.7.4. Recent Developments
 9.8. Medtronic plc (Ireland)
  9.8.1. Company Overview
  9.8.2. Company Financials
  9.8.3. Product Portfolio
  9.8.4. Recent Developments
 9.9. Stryker Corporation (U.S.)
  9.9.1. Company Overview
  9.9.2. Company Financials
  9.9.3. Product Portfolio
  9.9.4. Recent Developments
 9.10. Terumo Corporation (Japan)
  9.10.1. Company Overview
  9.10.2. Company Financials
  9.10.3. Product Portfolio
  9.10.4. Recent Developments
(Note: Financials are captured for public listed companies)

Key questions addressed by the research report-

Historic Period: 2018-2020, Base Year: 2020, Forecast Data: 2021-2026

Drug device combination market exhibits a compounded annual growth rate (CAGR) of 7.4 % from 2021 to 2026.

Prominent players in the drug device combination market are W. L. Gore & Associates Inc. Becton, Dickinson and Company, Teleflex Incorporated, Novartis International AG, Boston Scientific Corporation, AbbVie Inc., Abbott Laboratories, Medtronic plc, Stryker Corporation, Terumo Corporation.

North America and Asia Pacific offers numerous growth opportunities for companies in drug device combination market.

Transdermal patch segment leads the product market segment in 2020

Yes, the report offers comprehensive analysis of the COVID-19 pandemic on the market. The report comes with in-depth deviation analysis pre- and post-COVID-19 along with the market trends during the study period.

We follow our in-house domain-assisted cognition (DAC) research framework to compose all our market research reports. The framework ensures contextually relevant insights discovery by collecting precise market information via primary and secondary research.

Yes, we offer 15% free customization with the purchase of this report. Please Contact Us regarding your customization requirements and our research expert will connect with you within 12 hours.


    Have any question? Check your free sample before purchase or connect with our expert.

    Additional information

    Licensing Types

    , , ,

    Enquire about Drug Device Combination Market Analysis by Product (Infusion Pumps, Orthopaedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters, Photodynamic Therapy Devices, Wound Care Products, Transdermal Patches), and by Region - Forecast to 2026